华蟾素联合化疗治疗卵巢癌致恶性腹腔积液临床观察

详细信息    查看官网全文

• 英文论文题名：Clinical observation of cinobufacini combined with chemotherapy in the treatment of malignant ascites caused by ovarian cancer
• 论文作者：曲洪澜
• 英文论文作者：Qu Honglan ; Inner Mongolia Forestry General Hospital
• 年：2016
• 作者机构：内蒙古林业总医院血液肿瘤科;
• 论文关键词：华蟾素 ; 卵巢癌 ; 恶性腹腔积液 ; 灌注化疗
• 英文论文关键词：cinobufotalin ovarian cancer ; malignant peritoneal effusion ; perfusion chemotherapy
• 会议召开时间：2016-12-01
• 会议录名称：中国医师进修论文选编
• 语种：中文
• 分类号：R737.31
• 学会代码：BCLK
• 会议名称：2016年12月中国医师进修学术交流会
• 会议地点：中国北京
• 主办单位：中国医师进修编委会
• 学会名称：百川利康（北京）国际医学研究院
• 页数：4
• 文件大小：640k
• 原文格式：D
• 会议级别：全国

摘要

目的探讨腹腔灌注华蟾素联合静脉化疗治疗卵巢癌所致恶性腹腔积液的近期疗效及不良反应。方法:将2010年5月~2014年6月收治的90例经病理或细胞学确诊的卵巢癌所致恶性腹腔积液的患者随机分成两组。治疗组:腹腔灌注华蟾素(腹腔灌注华蟾素+利多卡因)化疗联合多西他赛全身化疗;对照组仅接受全身化疗,比较两组的近期疗效及不良反应。结果:两组患者腹水控制率分别为78%VS50%(P<0.05),生活质量分别为93.5%VS72.7%(P<0.05)差异均有统计学意义。两组患者不良反应发生率比较无统计学意义。结论:腹腔灌注联合化疗治疗卵巢癌所致恶性腹腔积液近期疗效优于单纯化疗组,且安全,患者耐受性好,值得临床推广。
objective to investigate the cinobufotalin abdominal cavity perfusion combined intravenous chemotherapy for breast cancer and ovarian malignant peritoneal effusion caused by the recent curative effect and adverse reactions. Methods:From May 2010 to June 2014 were 90 cases of breast and ovarian cancer confirmed by pathology or cytology and malignant peritoneal effusion patients were randomly divided into two groups. treatment group: peritoneal perfusion(cinobufotalin+ lidocaine) in abdominal cavity perfusion chemotherapy combined Docetaxel and systemic chemotherapy。The control group only received systemic chemotherapy. Observe two groups of hort-term curative effect and adverse reaction。Results: two groups of tumor the patient's quality of life were significantly improved, and the two groups of patients with ascites control rates were 78%, 50%(P < 0.05), the difference is statistically significant. Two groups of patients with adverse reaction rate were 41.3%, 40.9% has no statistical significance. Conclusion: abdominal hot perfusion chemotherapy for breast cancer and ovarian cancer caused by malignant peritoneal effusion in the near future curative effect is better than the pure chemotherapy group, and safe, good patient tolerance, worth clinical promotion.

引文

[1]孙燕.内科肿瘤学[M].北京:人民卫生出版社,2001:262-263
    [2]孙韬、左明焕、胡凯文.癌毒与恶性肿瘤[J].辽宁中医杂志,2011.38(2):261-263.
    [3]DE Bree E,Rosing H,Filis D.et al.Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel:a clinical and pharmacokinetic study[J].Ann Surg Oncol,2008,15(4):1183-1192
    [4]陈华、孙宇、崔晓楠.华蟾素注射液对人肝癌Hep G-2细胞DNA拓扑异构酶Ⅰ的影响[J].中国癌症杂志,2010,20(3):197-201
    [5]陈秀英.华蟾素注射液对人淋巴内皮细胞增殖、迁移和管状结构形成的影响[D].大连:大连医科大学,2012
    [6]刘浩.中药注射剂调控肿瘤血管生成信号传导通路的机制研究[D].北京:中国中医研究院,2005
    [7]罗展雄,倪秉强,郑青平等.华蟾素注射液对晚期恶性肿瘤患者T淋巴细胞亚群及NK细胞的影响[J].现代肿瘤医学,2009,17(2):340-341
    [8]何玉玲、邢莉清.华蟾素的药理作用及临床应用[J].中国临床医学药研究杂志,2003,8(90):8865-8867.
    [9]何山林,徐弘君,王学静.胸腹腔置微管引流并药物注入治疗恶性胸腹水186例[J].现代诊断与治疗,2005,16(1):53-54.